Results of an International Postmarketing Surveillance Study of pl-VEGF165 Safety and Efficacy in 210 Patients with Peripheral Arterial Disease

Abstract

IntroductionThe effective treatment of chronic lower limb ischemia is one of the most challenging issues confronting vascular surgeons. Current pharmacological therapies play an auxiliary role and cannot prevent disease progression, and new treatment methods are needed. pl-VEGF165, a gene therapy drug, was approved in Russia for the treatment of atherosclerotic peripheral arterial disease (PAD) after clinical studies in 2011. The study drug is an original gene construction in which pl-VEGF165 1.2 mg is the active substance.ObjectiveThis postmarketing surveillance study was undertaken to evaluate the safety (identification of uncommon side effects) and efficacy of gene therapy in patients in routine clinical practice.MethodsIn total, 210 patients with stage II–III chronic limb ischemia (according to the Fontaine classification modified by AV Pokrovsky) in 33 healthcare facilities in Russia and the Ukraine were enrolled in the study. The control group (n = 60) received conservative therapy without prostaglandins and prostacyclins, and the treatment group (n = 150) received treatment with pl-VEGF165 as two intramuscular injections for a total dose of 2.4 mg. Pain-free walking distance (PWD) (the primary efficacy criterion for Fontaine stages II–III), blood flow linear velocity (BFLV), and ankle-brachial index (ABI) were monitored for 6 months. The safety of pl-VEGF165 gene transfer in terms of the trial protocol was initially evaluated 6 months after the start of the study; adverse events (AEs) and serious adverse events (SAEs) were recorded during both routine visits and unscheduled requests for medical care.ResultsOverall, PWD increased by 177%, from 100.3 ± 6.9 to 277.1 ± 16.2 m (p = 0.0001), in the treatment group, whereas the mean value was unchanged in the control group (p = 0.218). Both BFLV and ABI values increased by 24% (p = 0.0001) in the treatment group but decreased in the control group. The greatest therapeutic effect was observed for stage III disease: PWD increased by 683% (p = 0.0001). No angiogenic therapy-related AEs or side effects were recorded, and target limb salvage was 96 and 97% in the treatment and control groups, respectively. The results obtained in this study are not significantly different from those observed in the phase IIb/III registration clinical study completed in 2011.Conclusionpl-VEGF165 intramuscular gene transfer is an effective treatment for moderate to severe claudication due to chronic lower limb ischemia in routine clinical practice.ClinicalTrials.gov identifier: NCT02369809.

Gene Therapy Using Plasmid DNA Encoding Vascular Endothelial Growth Factor 164 and Fibroblast Growth Factor 2 Genes for the Treatment of Horse Tendinitis and Desmitis: Case Reports

“…Moreover, in human clinical practice gene therapy pDNA encoding VEGF and FGF2 genes were used for the treatment of patients with critical lower limb ischemia ( 14 ). Finally, pDNA pl-VEGF165, encoding human VEGF165, demonstrated safety and efficacy in patients with chronic lower limb ischemia and was approved in Russia for the treatment of atherosclerotic peripheral arterial disease ( 18 , 19 ). The high efficacy and safety of the direct pDNA gene therapy has been demonstrated in all of these cases.…”

Hydrogel-Based Localized Nonviral Gene Delivery in Regenerative Medicine Approaches—An Overview

“…Due to its biosafety, current worldwide approved nonviral gene products have been mainly focused on the administration of naked pDNA molecules encoding for angiogenic factors (pDNA-HGF: Collategene [122]; pDNA-VEGF: Neovasculgen [123]) for the treatment of cardiovascular diseases [124]. Of note, the first RNAi drug product (Onpattro) was approved in 2018 and is based on a nonviral lipid nanoparticle and siRNA [125] for the treatment of hereditary transthyretin amyloidosis.…”

Pilot study of the safety and efficacy of angiogenic therapy in diabetic foot syndrome

“…При этом исследование показало, что применение индукции ангиогенеза было наиболее эффективно у пациентов с СД, которые составили 60% участников [11]. Отечественные исследования с участием больных хронической ишемией нижних конечностей показали, что у пациентов с фоновым СД локальная индукция ангиогенеза в нижних конечностях не сопровождается развитием нежелательных явлений [12]. Таким образом, результаты настоящего пилотного исследования подтверждают ранее накопленные доказательства безопасности ангиогенной терапии у пациентов с СД.…”